These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10547593)

  • 1. CD44 expression in benign, premalignant, and malignant ovarian neoplasms: relation to tumour development and progression.
    Saegusa M; Machida D; Hashimura M; Okayasu I
    J Pathol; 1999 Nov; 189(3):326-37. PubMed ID: 10547593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD44 expression in normal, hyperplastic, and malignant endometrium.
    Saegusa M; Hashimura M; Okayasu I
    J Pathol; 1998 Mar; 184(3):297-306. PubMed ID: 9614383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of DCC gene expression during ovarian tumorigenesis: relation to tumour differentiation and progression.
    Saegusa M; Machida D; Okayasu I
    Br J Cancer; 2000 Feb; 82(3):571-8. PubMed ID: 10682668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced expression of CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinoma.
    Pirinen R; Hirvikoski P; Böhm J; Kellokoski J; Moisio K; Virén M; Johansson R; Hollmén S; Kosma VM
    Hum Pathol; 2000 Sep; 31(9):1088-95. PubMed ID: 11014576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up.
    Lipponen P; Aaltoma S; Kosma VM; Ala-Opas M; Eskelinen M
    J Pathol; 1998 Oct; 186(2):157-64. PubMed ID: 9924431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of CD44 splice variant v10 in Hodgkin's disease is associated with aggressive behaviour and high risk of relapse.
    Beham-Schmid C; Heider KH; Hoefler G; Zatloukal K
    J Pathol; 1998 Dec; 186(4):383-9. PubMed ID: 10209487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
    Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
    Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased CD44 standard form expression correlates with prognostic variables in ovarian carcinomas.
    Ross JS; Sheehan CE; Williams SS; Malfetano JH; Szyfelbein WM; Kallakury BV
    Am J Clin Pathol; 2001 Jul; 116(1):122-8. PubMed ID: 11447742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD44 expression in sinonasal melanomas: is loss of isoform expression associated with advanced tumour stage?
    Regauer S; Ott A; Berghold A; Beham A
    J Pathol; 1999 Jan; 187(2):184-90. PubMed ID: 10365093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gains and losses of adhesion molecules (CD44, E-cadherin, and beta-catenin) during oral carcinogenesis and tumour progression.
    Bánkfalvi A; Krassort M; Buchwalow IB; Végh A; Felszeghy E; Piffkó J
    J Pathol; 2002 Nov; 198(3):343-51. PubMed ID: 12375267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of CD44 variant 6 expression in advanced extrahepatic bile duct/ampullary carcinoma.
    Yokoyama Y; Hiyama E; Murakami Y; Matsuura Y; Yokoyama T
    Cancer; 1999 Nov; 86(9):1691-9. PubMed ID: 10547541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer.
    Miyoshi T; Kondo K; Hino N; Uyama T; Monden Y
    Clin Cancer Res; 1997 Aug; 3(8):1289-97. PubMed ID: 9815811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
    Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I
    J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced CD44 standard expression is associated with tumour recurrence and unfavourable outcome in differentiated thyroid carcinoma.
    Böhm JP; Niskanen LK; Pirinen RT; Kiraly K; Kellokoski JK; Moisio KI; Eskelinen MJ; Tulla HE; Hollmen S; Alhava EM; Kosma VM
    J Pathol; 2000 Nov; 192(3):321-7. PubMed ID: 11054715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of CD44 splice variants in squamous epithelia and squamous cell carcinomas of the head and neck.
    Herold-Mende C; Seiter S; Born AI; Patzelt E; Schupp M; Zöller J; Bosch FX; Zöller M
    J Pathol; 1996 May; 179(1):66-73. PubMed ID: 8691348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of CD44 standard and isoforms in human breast cancer xenografts and shedding of soluble forms into serum of nude mice.
    Fichtner I; Dehmel A; Naundorf H; Finke LH
    Anticancer Res; 1997; 17(5A):3633-45. PubMed ID: 9413216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
    Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
    Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD44s and CD44v6 expression in localized T1-T2 conventional renal cell carcinomas.
    Daniel L; Lechevallier E; Giorgi R; Lindner V; De Fromont M; Vieillefond A; Coulange C; Figarella-Branger D
    J Pathol; 2001 Mar; 193(3):345-9. PubMed ID: 11241414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic significance of CD44s and CD44v6 expression in stage two breast carcinoma: an immunohistochemical study.
    Morris SF; O'Hanlon DM; McLaughlin R; McHale T; Connolly GE; Given HF
    Eur J Surg Oncol; 2001 Sep; 27(6):527-31. PubMed ID: 11520083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.